FDA Expands ASCENIV Label to Include Pediatric Patients as Young as Two Years for Primary Immunodeficiency Treatment
Key Insights
The FDA has approved ADMA Biologics' supplemental application to expand ASCENIV's indication to include pediatric patients aged 2 years and older with primary humoral immunodeficiency (search), lowering the previous age restriction from 12 years.
The approval represents completion of the required pediatric assessment post-marketing commitment and allows earlier treatment intervention for younger immune-compromised patients.
ASCENIV is a plasma-derived intravenous immune globulin manufactured using ADMA's patented donor screening methodology and tailored plasma pooling design that includes respiratory syncytial virus plasma.
ADMA Biologics announced that the U.S. Food and Drug Administration (search) has approved the company's supplemental Biologics License Application to expand the indication for ASCENIV (immune globulin intravenous, human – slra 10% liquid) to include pediatric patients aged 2 years and older with primary humoral immunodeficiency (search). The approval lowers the previous age restriction from 12 years and older, representing a significant expansion in the treatment population for this plasma-derived therapy.
Regulatory Milestone Addresses Pediatric Treatment Gap
The FDA approval represents the final study report for the pediatric assessment required as part of ADMA's post-marketing commitment. Previously, ASCENIV was restricted to primary immunodeficiency patients aged 12 years and older, leaving a treatment gap for younger children with these conditions.
"This expanded label for ASCENIV allows ADMA to actively address the treatment needs of younger PI and immune compromised patients earlier in their treatment journey," said Adam Grossman, President and Chief Executive Officer of ADMA Biologics.
Clinical Significance for Pediatric Immunodeficiency
Primary humoral immunodeficiency (search), also known as primary immune deficiency disease (search), affects patients' ability to produce adequate antibodies to fight infections. The expanded indication provides physicians with an FDA-approved treatment option for younger pediatric patients who previously had limited therapeutic choices.
Kaitlin Kestenberg, Chief Operating Officer and Senior VP of Compliance at ADMA, emphasized the collaborative effort required for the pediatric studies: "We proudly recognize the extraordinary collaboration of the PI disease community and dedicated physicians, along with the courage and commitment of the children and families whose participation was essential in driving this clinical program forward."
Product Characteristics and Manufacturing
ASCENIV is manufactured using ADMA's unique, patented plasma donor screening methodology and tailored plasma pooling design. The manufacturing process blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company's proprietary microneutralization assay. This approach results in a product containing naturally occurring polyclonal antibodies that help neutralize microbes such as bacteria and viruses.
The immune globulin was originally approved by the FDA in April 2019 and is protected by numerous issued patents in the United States and internationally.
Safety Profile and Monitoring Requirements
ASCENIV carries a boxed warning for thrombosis (search), renal dysfunction (search), and acute renal failure (search). Risk factors for thrombosis include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
For patients at risk of thrombosis (search), renal dysfunction (search), or renal failure, the product should be administered at the minimum dose and infusion rate practicable, with adequate hydration before administration. Healthcare providers must monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
The most common adverse reactions observed in clinical studies included headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea, occurring in 5% or more of study subjects. Additional risks include hypersensitivity reactions, aseptic meningitis syndrome, hemolytic anemia, and transfusion-related acute lung injury.